الصحة
New Radiotheranostic Agent Offers Targeted Therapy in Metastatic Kidney Cancer
Medical Xpress
أبرز النقاط
- The new 68Ga/177Lu-NYM096 agent both detects metastatic kidney cancer and provides targeted radiotherapy.
- The small molecule compound offers a safe strategy for late-stage patients by reducing common toxicity issues.
- The research was published in the September issue of The Journal of Nuclear Medicine.
Scientists have developed a new radiotheranostic pair called 68Ga/177Lu-NYM096. This agent can both detect tumors and deliver targeted radiotherapy in patients with metastatic clear cell renal cell carcinoma (ccRCC).
The method uses a small molecule compound to reduce toxicity issues commonly seen in existing treatments. This provides a safer and more feasible strategy for advanced-stage patients.
The research results were published in the September issue of The Journal of Nuclear Medicine.
تفاعل مع الخبر
#Metastatic Kidney Cancer#Radiotheranostics#Nuclear Medicine#Targeted Radiotherapy#Clear Cell Renal Cell Carcinoma
الخبر التاليKenya'da ilk Ebola ölüm kaydedildiاسأل عن هذا الخبر
الإجابات من الذكاء الاصطناعي، من هذا الخبر فقط.
الأسئلة الشائعة
- Which type of cancer was this new method developed for?
- It was developed for metastatic clear cell renal cell carcinoma (ccRCC).
- What is the main advantage of the radiotheranostic pair?
- It detects tumors while simultaneously applying targeted radiotherapy and reducing toxicity.
- In which journal was the research published?
- It was published in the September issue of The Journal of Nuclear Medicine.
هذا ملخّص قصير مُنشأ بالذكاء الاصطناعي. الخبر الكامل موجود في المصدر.
اقرأ الخبر كاملًا من المصدرmedicalxpress.comكيف ننتج محتوانا →أخبار ذات صلة
الصحة